FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1870251796> ?p ?o ?g. }

• W1870251796 endingPage "iv361" @default.
• W1870251796 startingPage "iv361" @default.
• W1870251796 abstract "ABSTRACT Aim: PD-L1 mediates cancer immune evasion, and blocking PD-L1 represents a cancer immunotherapy strategy that can restore tumor-specific T-cell immunity. MPDL3280A, a human monoclonal antibody containing an engineered Fc-domain, targets PD-L1, preventing binding to its receptors PD-1 and B7.1 on activated T cells. MPDL3280A does not disrupt the PD-L2/PD-1 interaction, which may mitigate autoimmune lung toxicity. As VEGF blockade is proposed to synergize with immunotherapy, and certain chemos may augment immune responses, we examined MPDL3280A with bev and/or chemo. Methods: This open-label, multicenter phase Ib study evaluated the safety and preliminary efficacy of MPDL3280A with bev (Arm A, refractory tumors or 1L renal cell carcinoma [RCC]) and bev + FOLFOX (Arm B, oxaliplatin-naive tumors) in pts with locally advanced or metastatic solid malignancies. Pts received MPDL3280A 20 mg/kg q3w (Arm A) or 15 mg/kg q2w (Arm B), and bev 15 mg/kg q3w (Arm A) or 10 mg/kg q2w (Arm B). Chemo was given at standard doses. Objective responses were assessed by RECIST 1.1. Results: As of Jan 21, 2014, 33 pts in Arm A and 29 pts in Arm B were treated; Arm A 1L RCC patients had short follow-up. Most pts had CRC (39% and 79% in Arms A and B, respectively). Grade 3/4 AEs regardless of attribution occurred in 42% of Arm A pts, including abdominal pain, hyperbilirubinemia, pneumonia and tumor pain (6% each), and in 52% of Arm B pts, including neutropenia (31%) and diarrhea (14%). No MPDL3280A-related infusion reactions occurred. SAEs occurred in 30% and 17% of pts in Arms A and B, respectively. RECIST responses were observed in 3 Arm A pts (CRC, melanoma, breast cancer) and 11 Arm B pts (10 CRC, 1 breast cancer). One Arm B pt (RCC) had a CR. Updated results will be presented. Conclusions: MPDL3280A + bev ± chemo was well tolerated and no unexpected toxicity was observed. Responses were observed in a variety of tumors. Further evaluation of MPDL3280A combination regimens in pts with advanced or metastatic solid tumors is warranted. Disclosure: C. Lieu: Sanofi Aventis consultant; J.D. Powderly: : Leadership position: Biologics Human Application Lab. Advisor: Genentech, BMS, Amplimmune, and Merck. BMS. Research funding: Genentech, BMS, Amplimmune, Merck, AstraZeneca, ImClone, and Eli Lilly. Speaker and advisor: BMS; H. Hochster: Genentech consultant; R. Funke, C. Rossi and D. Waterkamp: is an employee of Genentech, Inc.;H. Hurwitz: Research funding from Genentech, Roche, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron, GlaxoSmithKline, and Amgen. Advisor to Genentech, Roche, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron, GlaxoSmithKline, and Amgen. All other authors have declared no conflicts of interest." @default.
• W1870251796 created "2016-06-24" @default.
• W1870251796 creator A5003463083 @default.
• W1870251796 creator A5012289008 @default.
• W1870251796 creator A5015750678 @default.
• W1870251796 creator A5021453899 @default.
• W1870251796 creator A5028472820 @default.
• W1870251796 creator A5033313503 @default.
• W1870251796 creator A5046311492 @default.
• W1870251796 creator A5073403998 @default.
• W1870251796 creator A5087706822 @default.
• W1870251796 creator A5090977453 @default.
• W1870251796 date "2014-09-01" @default.
• W1870251796 modified "2023-10-16" @default.
• W1870251796 title "Safety and Efficacy of Mpdl3280A (Anti-Pdl1) in Combination with Bevacizumab (Bev) and/or Chemotherapy (Chemo) in Patients (Pts) with Locally Advanced or Metastatic Solid Tumors" @default.
• W1870251796 doi "https://doi.org/10.1093/annonc/mdu342.2" @default.
• W1870251796 hasPublicationYear "2014" @default.
• W1870251796 type Work @default.
• W1870251796 sameAs 1870251796 @default.
• W1870251796 citedByCount "19" @default.
• W1870251796 countsByYear W18702517962015 @default.
• W1870251796 countsByYear W18702517962016 @default.
• W1870251796 countsByYear W18702517962018 @default.
• W1870251796 countsByYear W18702517962020 @default.
• W1870251796 countsByYear W18702517962022 @default.
• W1870251796 crossrefType "journal-article" @default.
• W1870251796 hasAuthorship W1870251796A5003463083 @default.
• W1870251796 hasAuthorship W1870251796A5012289008 @default.
• W1870251796 hasAuthorship W1870251796A5015750678 @default.
• W1870251796 hasAuthorship W1870251796A5021453899 @default.
• W1870251796 hasAuthorship W1870251796A5028472820 @default.
• W1870251796 hasAuthorship W1870251796A5033313503 @default.
• W1870251796 hasAuthorship W1870251796A5046311492 @default.
• W1870251796 hasAuthorship W1870251796A5073403998 @default.
• W1870251796 hasAuthorship W1870251796A5087706822 @default.
• W1870251796 hasAuthorship W1870251796A5090977453 @default.
• W1870251796 hasBestOaLocation W18702517961 @default.
• W1870251796 hasConcept C121608353 @default.
• W1870251796 hasConcept C126322002 @default.
• W1870251796 hasConcept C143998085 @default.
• W1870251796 hasConcept C2776694085 @default.
• W1870251796 hasConcept C2777802072 @default.
• W1870251796 hasConcept C2993640289 @default.
• W1870251796 hasConcept C71924100 @default.
• W1870251796 hasConceptScore W1870251796C121608353 @default.
• W1870251796 hasConceptScore W1870251796C126322002 @default.
• W1870251796 hasConceptScore W1870251796C143998085 @default.
• W1870251796 hasConceptScore W1870251796C2776694085 @default.
• W1870251796 hasConceptScore W1870251796C2777802072 @default.
• W1870251796 hasConceptScore W1870251796C2993640289 @default.
• W1870251796 hasConceptScore W1870251796C71924100 @default.
• W1870251796 hasLocation W18702517961 @default.
• W1870251796 hasOpenAccess W1870251796 @default.
• W1870251796 hasPrimaryLocation W18702517961 @default.
• W1870251796 hasRelatedWork W2047800909 @default.
• W1870251796 hasRelatedWork W2119336542 @default.
• W1870251796 hasRelatedWork W2417717847 @default.
• W1870251796 hasRelatedWork W2488041581 @default.
• W1870251796 hasRelatedWork W2588654018 @default.
• W1870251796 hasRelatedWork W4221044984 @default.
• W1870251796 hasRelatedWork W4231596293 @default.
• W1870251796 hasRelatedWork W4238549103 @default.
• W1870251796 hasRelatedWork W4376644351 @default.
• W1870251796 hasRelatedWork W4380186280 @default.
• W1870251796 hasVolume "25" @default.
• W1870251796 isParatext "false" @default.
• W1870251796 isRetracted "false" @default.
• W1870251796 magId "1870251796" @default.
• W1870251796 workType "article" @default.